Department of Dermatology

Comparative Analysis of Radiomic Features and Gene Expression Profiles in Histopathology Data using Graph Neural Networks (2024) Rivera Monroy L, Rist L, Eberhardt M, Ostalecki C, Bauer A, Vera J, Breininger K, Maier A Conference contribution Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches (2024) Welsh JA, Goberdhan DC, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, et al. Journal article Identifizierung von Biomarkern und neuen therapeutischen Zielen beim Aderhautmelanom (2024) Wessely A, Koch E, Vera J, Berking C, Heppt M Journal article Clinical characteristics and treatment modalities in uremic and non uremic calciphylaxis - a dermatological single-center experience (2024) Yousuf S, Busch D, Renner R, Schliep S, Erfurt-Berge C Journal article Optimizing immune checkpoint blockade in metastatic uveal melanoma: exploring the association of overall survival and the occurrence of adverse events (2024) Koch E, Petzold A, Dippel E, Erdmann M, Gesierich A, Gutzmer R, Hassel JC, et al. Journal article The Current State of Systemic Therapy of Metastatic Uveal Melanoma (2024) Koch E, Heppt M, Berking C Journal article Stringent monitoring can decrease mortality of immune checkpoint inhibitor induced cardiotoxicity (2024) Wang Y, Ertl C, Schmitt C, Hammann L, Kramer R, Grabmaier U, Schöberl F, et al. Journal article Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS). (2024) Thaçi D, Pinter A, Sebastian M, Termeer C, Sticherling M, Gerdes S, Schäkel K, et al. Journal article Exosomal ROR1 in peritoneal fluid identifies peritoneal disseminated PDAC and is associated with poor survival (2024) Mittelstädt A, Anthuber A, David P, Podolska M, Benard A, Brunner M, Krautz C, et al. Journal article Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. (2024) Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, et al. Journal article